secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aligos Therapeutics, Inc. (ALGS)
CIK:        0001799448
Form:       8-K
Filed at:   2022-03-22T23:59:59+00:00
Accession:  0001193125-22-081126
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Aligos discontinues hepatitis B drug ALG-020572 after patient hospitalized with ALT flare
--------------------------------------------------------------------------------

- Discontinued ALG-020572 (ASO for chronic hepatitis B) after one subject hospitalized and three others experienced ALT flares following 210 mg multiple dosing.
- Dosing in first CHB cohort of Study 401 stopped after serious adverse event (ALT increase, brief hospitalization).
- All four affected subjects improving; hospitalized subject discharged. No further details on safety provided.
- Cost savings from discontinuation to fund clinical and preclinical programs in CHB, NASH, and COVID-19.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1799448/000119312522081126/0001193125-22-081126-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1799448/000119312522081126/d320642d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-081126

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer